surpass cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT In patients with type 2

Risk of bias assessment Four authors independently assessed the risk of bias (RoB) using version 2 of the Cochrane RoB tool for randomized trials (RoB 2) within the Review Manager (RevMan) computer program, version 7.2.0 (Cochrane Collaboration, London, UK) [20,21]

Tinnitus affects 1015% of adults and can arise from numerous causes including age-related hearing loss, noise exposure, ear infections, cardiovascular conditions, and certain medications

Expiration dates may be extended after real-time data confirms longer-than-expected stability

These effects may contribute to metabolic improvements beyond what can be explained by weight loss alone

The clinic operates on a cash-pay model and doesnt assist with prior authorizations or insurance billing, so all payments are out of pocket